Last reviewed · How we verify

NCT04944433

Safety and Efficacy of the Coronavirus Disease 2019 Vaccine in Hemodialysis Patients

Completed Last updated 5 August 2022
What this trial tests

trial in Coronavirus Disease 2019 Vaccines in 950 participants. Completed in 4 August 2022.

Timeline
9 April 2021
Primary endpoint
4 August 2022
4 August 2022

Quick facts

Lead sponsorHospital Italiano de Buenos Aires
StatusCompleted
Study typeOBSERVATIONAL
Enrollment950
Start date9 April 2021
Primary completion4 August 2022
Estimated completion4 August 2022
Sites1 location across Argentina

Conditions studied

Sponsor

Hospital Italiano de Buenos Aires

Who can join

18 and older, any sex, with Coronavirus Disease 2019 Vaccines or Renal Dialysis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

It is unknown whether Coronavirus disease 2019 vaccines confer the same high level of protection in patients with kidney disease as reported for participants in recent trials, who were generally healthy. Objectives: To evaluate the safety and efficacy of Coronavirus disease 2019 vaccines in hemodialysis patients.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Safety and Effectiveness of COVID-19 SPUTNIK V Vaccine in Dialysis Patients
    Rosa-Diez G, Papaginovic Leiva MM, Lombi F, Crucelegui MS, et al · · 2021 · cited 1× · DOI 10.1101/2021.10.21.21265349

Verify or expand the search:

Other Hospital Italiano de Buenos Aires trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04944433.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing